Trade

with

Sunesis Pharmaceuticals Inc
(NASDAQ: SNSS)
AdChoices
1.44
+0.08
+5.88%
After Hours :
-
-
-

Open

1.40

Previous Close

1.36

Volume (Avg)

3.00M (2.01M)

Day's Range

1.36-1.44

52Wk Range

1.00-8.46

Market Cap.

87.04M

Dividend Rate ( Yield )

-

Beta

2.52

Shares Outstanding

60.44M

P/E Ratio (EPS)

-

AdChoices
Fundamentals
  • Key statistics
  • Growth
  • Profitability
  • Financial health
  • Price ratios
  • Trading statistics
  • Management effectiveness
Industry Biotechnology
Highlights
Analyst Recommendation: Hold
    • Revenue

    • 7.96M

    • Net Income

    • -34.60M

    • Market Cap.

    • 87.04M

    • Enterprise Value

    • -

    • Net Profit Margin %

    • -516.68

    • PEG (Price/Earnings Growth) Ratio

    • -

    • Beta

    • 2.52

    • Forward P/E

    • -2.68

    • Price/Sales

    • 10.05

    • Price/Book Value

    • 5.49

    • Price/Cash flow

    • -1.72

      • EBITDA

      • -31.66M

      • Return on Capital %

      • -74.56

      • Return on Equity %

      • -818.42

      • Return on Assets %

      • -74.56

      • Book Value/Share

      • 0.26

      • Shares Outstanding

      • 60.44M

      • Last Split Factor (Date)

      • -

      • Last Dividend (Ex-Date)

      • -

      • Dividend Declaration Date

      • -

      Analyst Recommendation
      10/17/2014
      Hold
        • 1 Year Price Target

        • 3.70

        • Credit Rating

        • -

        • Analysts

        • 5

        • EPS Estimate

        • -0.62

        • Cashflow Estimate

        • -0.73

        Morningstar Consensus estimate data
        • Growth Rate (%)

        • Company

        • Industry

          • Sales (Revenue)

            Q/Q (last year)

          • 0.00

          • 40.73

          • Net Income

            YTD/YTD (last year)

          • -

          • 17.04

          • Net Income

            Q/Q (last year)

          • -

          • 98.90

          • Sales (Revenue)

            5-Year Annual Average

          • 7.99

          • 63.43

          • Net Income

            5-Year Annual Average

          • -

          • 10.65

          • Dividends

            5-Year Annual Average

          • -

          • 15.81

          • Profit Margins (%)

          • Company

          • Industry

            • Gross Margin

            • 100.00

            • 82.75

            • Pre-Tax Margin

            • -516.68

            • 39.38

            • Net Profit Margin

            • -516.68

            • 31.33

            • Average Gross Margin

              5-Year Annual Average

            • 100.00

            • 82.99

            • Average Pre-Tax Margin

              5-Year Annual Average

            • -

            • 33.42

            • Average Net Profit Margin

              5-Year Annual Average

            • -15,626.20

            • 199.05B

            • Financial Ratios

            • Company

            • Industry

              • Debt/Equity Ratio

              • 0.27

              • 0.76

              • Current Ratio

              • 1.51

              • 2.92

              • Quick Ratio

              • 1.48

              • 2.35

              • Interest Coverage

              • -16.62

              • 38.02

              • Leverage Ratio

              • 3.77

              • 2.21

              • Book Value/Share

              • 0.26

              • 4.76

              • Price Ratios

              • Company

              • Industry

                • Current P/E Ratio

                • -1.68

                • 188.68

                • P/E Ratio 5-Year High

                • -19.70

                • 634.30

                • P/E Ratio 5-Year Low

                • -1.35

                • 124.82

                • Price/Sales Ratio

                • 8.66

                • 8.72

                • Price/Book Value

                • 4.73

                • 7.95

                • Price/Cash Flow Ratio

                • -1.72

                • 45.45

                • Key Metrics

                • Company

                  • Shares Short

                    as of -

                  • -

                  • Short Ratio

                    as of -

                  • -

                  • Short % of Float

                    as of -

                  • -

                  • Shares Short

                    prior month

                  • -

                  • Trailing Annual Dividend Yield

                  • -

                  • 5 Year Average Dividend Yield

                  • -

                  • Key Metrics

                  • Company

                    • Payout Ratio

                    • -

                    • Dividend Date

                    • -

                    • Ex-Dividend Date

                    • -

                    • Last Split Factor

                      new per old

                    • -

                    • Last Split Date

                    • -

                    • Key Metrics

                    • Company

                    • Industry

                      • Return on Equity %

                        (5-Year Average)

                      • -818.42

                        (-)

                      • 37.63

                        (27.20)

                      • Return on Assets %

                        (5-Year Average)

                      • -74.56

                        (-202.40)

                      • 17.22

                        (13.81)

                      • Return on Capital %

                        (5-Year Average)

                      • -169.30

                        (-)

                      • 21.78

                        (17.31)

                      • Income/Employee

                      • -

                      • 117.08k

                      • Inventory Turnover

                      • -

                      • 1.48

                      • Asset Turnover

                      • 0.14

                      • 0.55

                      Current Historical
                      Financials
                      • Income Statement
                      • Balance Sheet
                      • Cash Flow
                      Operating Income
                      -31.77M
                      Operating Margin
                      -399.36
                      Total Equity
                      -
                      Retained Earnings
                      -
                      Free Cashflow
                      -
                      Price/Cashflow
                      -1.72
                      Ownership

                      Institutional Ownership

                      -

                      Top 10 Institutions

                      80.54%

                      Mutual Fund Ownership

                      31.09%

                      Float

                      61.64%

                      5% / Insider Ownership

                      3.19%

                      Corporate insiders or major stockholders reporting trading activity in the stock.

                      Top Mutual Fund Owners

                      Top Institutional Owners

                      Mutual Fund Name

                      Institution Name

                      • Mutual Fund Name

                      • Shares Held

                      • % Change

                      • % Outstanding

                      • Fidelity® Select Biotechnology Portfolio

                      •  

                        3,100,478

                      • 6.54

                      • 5.13

                      • T. Rowe Price Health Sciences Fund

                      •  

                        2,024,800

                      • -0.32

                      • 3.36

                      • Eagle Small Cap Growth Fund

                      •  

                        1,920,448

                      • 80.23

                      • 3.18

                      • Vanguard Total Stock Mkt Idx

                      •  

                        846,347

                      • 0.00

                      • 1.40

                      • iShares Russell 2000 (AU)

                      •  

                        782,635

                      • -1.00

                      • 0.26

                      • UBS (Lux) EF Biotech (USD)

                      •  

                        664,900

                      • 0.00

                      • 1.10

                      • Fidelity Advisor® Biotechnology Fund

                      •  

                        602,217

                      • 35.87

                      • 1.00

                      • AXA Framlington Biotech

                      •  

                        591,155

                      • 0.00

                      • 1.00

                      • Franklin Biotechnology Discovery Fund

                      •  

                        577,400

                      • 0.00

                      • 0.96

                      • Institution Name

                      • Shares Held

                      • % Change

                      • % Outstanding

                      • Fidelity Management and Research Company

                      •  

                        5,893,898

                      • -4.40%

                      • 9.79

                      • NEA Management Company, LLC

                      •  

                        5,636,573

                      • 0.00%

                      • 9.36

                      • RA Capital Management, LLC

                      •  

                        4,869,261

                      • 0.00%

                      • 8.09

                      • Visium Asset Management LLC

                      •  

                        4,526,750

                      • 0.00%

                      • 7.52

                      • Eagle Asset Management, Inc.

                      •  

                        2,342,041

                      • +100.94%

                      • 3.87

                      Company Profile

                      Sector

                      Healthcare

                      Industry

                      Biotechnology

                      Type

                      Speculative Growth

                      Style

                      Small Growth

                      Sunesis Pharmaceuticals, Inc., was incorporated in the state of Delaware on February 10, 1998. It is a biopharmaceutical company focused on the development and commercialization of new oncology therapeutics for the treatment of solid...more and hematologic cancers. It currently focuses on the development of vosaroxin for the treatment of acute myeloid leukemia, or AML. Vosaroxin is a first-in-class anti-cancer quinolone derivative, or AQD—a class of compounds that has not been used previously for the treatment of cancer. AQDs have been shown to mediate anti-tumor activity by targeting mammalian topoisomerase II, an enzyme critical for cell replication. It has built an experienced cancer drug development organization committed to advancing vosaroxin in multiple indications to improve the lives of people wit...moreh cancer. In December 2010, the Company commenced enrollment of a Phase 3, multi-national, randomized, double-blind, placebo-controlled, pivotal trial of vosaroxin in combination with cytarabine in patients with relapsed or refractory AML, or the VALOR trial. The VALOR trial is designed to evaluate the effect of vosaroxin in combination with cytarabine, a widely used chemotherapy in AML, on overall survival as compared to placebo in combination with cytarabine. The Company owns development and commercialization rights to vosaroxin. It faces competition from many pharmaceutical, biopharmaceutical and biotechnology companies that are researching, developing and marketing products designed to address the treatment of cancer, including AML and ovarian cancer. In addition to regulations in the United States, the Company is subject to foreign regulations governing clinical trials and commercial sales and distribution of vosaroxin or its future drug candidates, if any.lessless

                      Key People

                      Daniel N. Swisher,Jr

                      CEO/President/Director

                      James W. Young,PhD

                      Chairman of the Board/Director

                      Eric H. Bjerkholt

                      CFO/Chief Accounting Officer/Executive VP, Divisional/Secretary

                      Adam R. Craig

                      Chief Medical Officer/Executive VP, Divisional

                      Joseph I. DePinto

                      Executive VP/Other Executive Officer

                      • Sunesis Pharmaceuticals Inc

                      • 395 Oyster Point Boulevard

                      • South San Francisco, CA 94080

                      • USA.Map

                      • Phone: +1 650 266-3500

                      • Fax: +1 650 266-3501

                      • sunesis.com

                      Incorporated

                      1998

                      Employees

                      32

                      Send Feedback

                      We appreciate your input!

                      • I'm having trouble signing into my Microsoft account

                      • I’m having problems with the services stripe (Mail, Facebook, etc.)

                      • There is an issue with my weather information

                      • I see an error in the content

                      • Other

                      Please give an overall site rating: